SARS-CoV-2 infection is associated with higher chance of diabetes remission among Veterans with incident diabetes.

<h4>Objective</h4>To examine the impact of SARS-CoV-2 on long-term glycemia.<h4>Research design and methods</h4>We conducted a retrospective inception cohort study using Veterans Health Administration data (March 1, 2020-May 31, 2022) among individuals with ≥ 1 positive nasal...

Full description

Saved in:
Bibliographic Details
Main Authors: Pandora L Wander, Elliott Lowy, Anna Korpak, Lauren A Beste, Steven E Kahn, Edward J Boyko
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0317348
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850143391048794112
author Pandora L Wander
Elliott Lowy
Anna Korpak
Lauren A Beste
Steven E Kahn
Edward J Boyko
author_facet Pandora L Wander
Elliott Lowy
Anna Korpak
Lauren A Beste
Steven E Kahn
Edward J Boyko
author_sort Pandora L Wander
collection DOAJ
description <h4>Objective</h4>To examine the impact of SARS-CoV-2 on long-term glycemia.<h4>Research design and methods</h4>We conducted a retrospective inception cohort study using Veterans Health Administration data (March 1, 2020-May 31, 2022) among individuals with ≥ 1 positive nasal swab for SARS-CoV-2 and individuals with ≥ 1 laboratory test of any type but no positive swab. Two incident diabetes cohorts were defined based on: 1) a computable phenotype using a combination of diagnosis codes, laboratory tests, and receipt of glucose-lowering medications (n = 17,754); and 2) the presence of ≥ 2 HbA1c results ≥ 6.5% (n = 4,768). We fit log-binomial models examining associations of SARS-CoV-2 with diabetes remission, defined as ≥ 2 HbA1c measurements < 6.5% ≥ 90 days apart after cessation of any glucose-lowering medications. To help equalize laboratory surveillance of glycemia, we conducted a subgroup analysis among non-hospitalized participants.<h4>Results</h4>In cohorts 1 and 2 respectively, 25% and 29% had ≥ 1 positive test for SARS-CoV-2 prior to enrollment, and 21% and 11% had remission. SARS-CoV-2 was associated with a higher chance of remission by both definitions (1: RR 1.22 [95%CI 1.14-1.29]; 2: RR 1.27 [95%CI 1.07-1.50]) over an average 503 (±202) and 494 (±184) days. The association was attenuated among non-hospitalized participants (1: RR 1.11 [1.04-1.20]; 2: R: 1.17 [95%CI 0.97-1.42]).<h4>Conclusions</h4>Diabetes remission was more common in Veterans with new-onset diabetes after SARS-CoV-2. In non-hospitalized participants, who were likely to have more similar laboratory surveillance, the association was diminished. Differences in surveillance or transient hyperglycemia may explain the observed association.
format Article
id doaj-art-6a4a2d0d8a5540c4867686caf7f006ec
institution OA Journals
issn 1932-6203
language English
publishDate 2025-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-6a4a2d0d8a5540c4867686caf7f006ec2025-08-20T02:28:42ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01202e031734810.1371/journal.pone.0317348SARS-CoV-2 infection is associated with higher chance of diabetes remission among Veterans with incident diabetes.Pandora L WanderElliott LowyAnna KorpakLauren A BesteSteven E KahnEdward J Boyko<h4>Objective</h4>To examine the impact of SARS-CoV-2 on long-term glycemia.<h4>Research design and methods</h4>We conducted a retrospective inception cohort study using Veterans Health Administration data (March 1, 2020-May 31, 2022) among individuals with ≥ 1 positive nasal swab for SARS-CoV-2 and individuals with ≥ 1 laboratory test of any type but no positive swab. Two incident diabetes cohorts were defined based on: 1) a computable phenotype using a combination of diagnosis codes, laboratory tests, and receipt of glucose-lowering medications (n = 17,754); and 2) the presence of ≥ 2 HbA1c results ≥ 6.5% (n = 4,768). We fit log-binomial models examining associations of SARS-CoV-2 with diabetes remission, defined as ≥ 2 HbA1c measurements < 6.5% ≥ 90 days apart after cessation of any glucose-lowering medications. To help equalize laboratory surveillance of glycemia, we conducted a subgroup analysis among non-hospitalized participants.<h4>Results</h4>In cohorts 1 and 2 respectively, 25% and 29% had ≥ 1 positive test for SARS-CoV-2 prior to enrollment, and 21% and 11% had remission. SARS-CoV-2 was associated with a higher chance of remission by both definitions (1: RR 1.22 [95%CI 1.14-1.29]; 2: RR 1.27 [95%CI 1.07-1.50]) over an average 503 (±202) and 494 (±184) days. The association was attenuated among non-hospitalized participants (1: RR 1.11 [1.04-1.20]; 2: R: 1.17 [95%CI 0.97-1.42]).<h4>Conclusions</h4>Diabetes remission was more common in Veterans with new-onset diabetes after SARS-CoV-2. In non-hospitalized participants, who were likely to have more similar laboratory surveillance, the association was diminished. Differences in surveillance or transient hyperglycemia may explain the observed association.https://doi.org/10.1371/journal.pone.0317348
spellingShingle Pandora L Wander
Elliott Lowy
Anna Korpak
Lauren A Beste
Steven E Kahn
Edward J Boyko
SARS-CoV-2 infection is associated with higher chance of diabetes remission among Veterans with incident diabetes.
PLoS ONE
title SARS-CoV-2 infection is associated with higher chance of diabetes remission among Veterans with incident diabetes.
title_full SARS-CoV-2 infection is associated with higher chance of diabetes remission among Veterans with incident diabetes.
title_fullStr SARS-CoV-2 infection is associated with higher chance of diabetes remission among Veterans with incident diabetes.
title_full_unstemmed SARS-CoV-2 infection is associated with higher chance of diabetes remission among Veterans with incident diabetes.
title_short SARS-CoV-2 infection is associated with higher chance of diabetes remission among Veterans with incident diabetes.
title_sort sars cov 2 infection is associated with higher chance of diabetes remission among veterans with incident diabetes
url https://doi.org/10.1371/journal.pone.0317348
work_keys_str_mv AT pandoralwander sarscov2infectionisassociatedwithhigherchanceofdiabetesremissionamongveteranswithincidentdiabetes
AT elliottlowy sarscov2infectionisassociatedwithhigherchanceofdiabetesremissionamongveteranswithincidentdiabetes
AT annakorpak sarscov2infectionisassociatedwithhigherchanceofdiabetesremissionamongveteranswithincidentdiabetes
AT laurenabeste sarscov2infectionisassociatedwithhigherchanceofdiabetesremissionamongveteranswithincidentdiabetes
AT stevenekahn sarscov2infectionisassociatedwithhigherchanceofdiabetesremissionamongveteranswithincidentdiabetes
AT edwardjboyko sarscov2infectionisassociatedwithhigherchanceofdiabetesremissionamongveteranswithincidentdiabetes